RxDoctor Payments Data

Adelaida Gyurjyan-Bunch, MD

Dermatology · Newport News, VANPI 1760845986

Payments from drug & device makers

$7,520in general payments, 2019–2025

Across 325 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$865
  • UCB, Inc.$806
  • LEO Pharma Inc.$473
  • Regeneron Healthcare Solutions, Inc.$450
  • Amgen$429
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$7,23596%
  • Education$2854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,520 in reported general payments places this provider in the 75th percentile of 396 dermatology providers in Virginia.

See all dermatology providers in Virginia

Medicare billing

Part B allowed, 2024
$224,506
Medicare patients
766
Services billed
4,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$237,959
Dupixent PenDupilumab29$111,952
Cimzia (2 Pack)Certolizumab Pegol12$68,247
Ketoconazole138$2,945
Metronidazole39$2,679
Clindamycin Phosphate41$1,751
Fluorouracil23$1,404
Clobetasol Propionate40$1,131
Fluocinonide22$968
Doxycycline Monohydrate42$755
Mupirocin102$649
Hydroxychloroquine Sulfate11$615
Triamcinolone Acetonide94$605
Hydrocortisone53$269
Doxycycline Hyclate11$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$806$68,24712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 396 dermatology providers in Virginia.

Other dermatology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →